MiniMedTM 780G system Insulin pump technology

The only system with Mean Detection™ technology* that provides automatic adjustments and corrections to glucose levels every 5 minutes

Request an in-service


Mean Detection™ technology     |     Clinical evidence     |     Ease of use     |     Recommended settings     |    
Components and apps     |     FAQ

Patient burnout is real

The need for advanced automation

Male looking frustrated while looking at a meal.

Unknown glucose variables
42 factors may affect blood glucose levels1

Bolusing for meals
33% of high glucose episodes are not followed by a correction bolus2

Carb counting
When tested on carb counting accuracy, people with type 1 diabetes underestimated carbohydrates 63% of the time3
50% of patients consider counting carbs the most burdensome aspect of managing diabetes4

What is Mean Detection™ technology?

The MiniMed™ 780G system uses current and past sensor glucose trends to detect a missed meal bolus*


If the system detects a meal based on the sensor glucose rising rate of change, it can automatically deliver stronger correction doses while sensor glucose values are rising, up to every 5 minutes. 

To learn more about how Mean Detection™ technology works, watch this video featuring distinguished engineer, Lou Lintereur.

Clinical evidence

Studied across various levels of starting therapy type and glycemic control

Children/Adolescent real-world evidence (ages ≤ 15)*

Children/Adolescent population achieved 78.9% time in range with a 100mg/dL target

Children/Adolescent Population5
Typically harder to manage

Real-world evidence (ages 7+)*

Real-world evidence for all ages showed 80.8% time in range with recommended settings using the MiniMed 780G insulin pump system.

Real-world evidence - ages 7 and over5
Diverse population across the globe

US pivotal - study design: Single-arm*

United States Pivotal study shows 78.8% time in range with recommended settings

Hybrid closed loop/SA6
Population that is typically well controlled




ADAPT randomized control study showed 70.1% time in range with recommended pump settings.

MDI + isCGM7
Population resistant to pump therapy not meeting glycemic targets

Clinical summaries


Due to inherent analysis limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.

Designed for ease of use

Improvements made with both patients and healthcare providers in mind

Sensor icon

NEW Guardian™ 4 sensor
No fingersticks with SmartGuard™ technology§ and less interaction required, reducing the number of alerts

Medtronic Extended infusion set icon

NEW Medtronic Extended™ infusion set
Only infusion set that doubles wear time up to 7 days for fewer interruptions||

Utensil icon

Mean Detection™ technology
Automatically adjusts and corrects blood glucose every 5 minutes

Smile icon

Quality of life
94% of users are satisfied with the impact of the MiniMed™ 780G system on their glucose level control and quality of life8

Recommended settings

Safely treats to the lowest glucose target available without increasing hypoglycemia when using recommended settings5

Recommended settings of 100 mg/dL and 2 hr AIT have shown consistent results globally.Real-world results in adults showed patients achieved up to 80% Time in Range with recommended settings without increasing hypoglycemia.5

Auto basal

100 mg/dL (default)

110 mg/dL
120 mg/dL

Auto correction

120 mg/dL
(default is set to on)

User-initiated corrections

120 mg/dL
(fixed target)

Components and apps

MiniMed™ 780G system


1. MiniMed™ 780G insulin pump
with advanced SmartGuard™ technology

2. Guardian™ 4 sensor and transmitter
with no fingersticks with SmartGuard™ automation§

3. Medtronic Extended™ infusion set
for up to 7 days of wear||

4. MiniMed™ Mobile app
Allows patients to view glucose levels, pump information, and insulin data on their phone or Apple Watch. View this reference chart for a list of compatible smartphones.


MiniMed 780G insulin pump system components.

MiniMed Mobile App Home Screen

MiniMed™ Mobile app
For patients

  • Displays pump and CGM data with customizable alerts
  • Time in Range viewed on demand
CareLink Connect mobile app home screen.

CareLink™ Connect app
For care partners

  • All-in-one viewing and customizable alerts of patient's pump and CGM data

Upgrade your patients to the MiniMed™ 780G system

Through April 27, 2024, we are offering software upgrade programs to switch your patients currently using MiniMed™ 770G to MiniMed™ 780G technology at no cost. The MiniMed™ 780G system does more of the work, meaning less for your patients to do. Help them switch to our most advanced innovation in diabetes therapy by taking advantage of this limited-time software upgrade.

Woman holding a mobile phone with software upgrade message displayed on screen.

Athletic man wearing the MiniMed 780G system.

CGM4U program

Using the Guardian™ 4 CGM can help patients get the most out of the MiniMed™ 780G system with SmartGuard™ technology. For a limited time, there are several offers available through our CGM4U program to convert patients to Guardian™ 4 CGM technology at low cost.

Request an in-service

This form is for Healthcare Professionals. If you are a patient looking for more information, click here

* Indicates a required field.

Your information will be used and protected in accordance with our privacy statement.

Frequently asked questions

Expand All

Who is this MiniMed™ 780G system recommended for?

Is a prescription required for the MiniMed™ 780G system?

Has Medicare approved the MiniMed™ 780G system?

When will ordering and shipping begin?

Are patients using the MiniMed™ 770G system eligible for an upgrade?

What are the recommended settings for the MiniMed™ 780G system?

Do patients need to do fingersticks when using the Guardian™ 4 sensor?

Can patients use the Guardian™ Sensor 3 with the MiniMed™ 780G insulin pump?

Does the MiniMed™ 780G system communicate with a smartphone?

What's unique about the MiniMed™ 780G system?

Is the MiniMed™ 780G insulin pump waterproof?

Where can I learn more about the MiniMed™ 780G system?

Your partner in diabetes care

Services and support designed with your patients in mind

Online learning icon
Medtronic Diabetes Digital University (MDDU) provides learning at your own pace. Learn more about MDDU

Dollar sign icon
Medtronic offers financial support programs to help make access to diabetes therapy more affordable for everyone. Terms and conditions apply. Learn more.

Book  icon
Browse our library to find reference materials for our Medtronic Diabetes products. User guides and manuals


Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating

Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off

Refers to SmartGuard™ feature. Individual results may vary


Fingersticks required in manual mode & to enter SmartGuard™. If symptoms don’t match alerts & readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard™


The extended wear infusion set can be worn for up to 7 days. Current infusion sets are recommended for up to 3 days of wear

Recommended settings in adults: SmartGuard™ Target: 100 mg/dL, 2 hr AIT, ages <=15: Start at SmartGuard™ Target: 110mg/Dl and reduce to 100 mg/Dl if no hypos, 2 hr AIT


Meade LT et al.. Clin Diabetes. 2016;34(3):142-147      


Sarah C.Westen, Jennifer L.Warnick, Anastasia Albanese-O’Neill, et al. Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy. Journal of Pediatric Psychology, 44(1), 2019, 21–31.


Brazeau AS, et al. Diabetes Res Clin Pract. 2013;99:19-23.


Data on file. Medtronic. Northridge, CA. Survey data AHCL Positioning Concept Test, 2019.


Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714.


Data on file from CIP 321: Pivotal Trial (Age 14-75). N=152. 2020; 16 US sites.


Choudhary P. et al, Lancet Diabetes Endocrinol. 2022; S2213-8587(22)00212-1


Medtronic data on file: MiniMed™ 780G users survey conducted in April – May 2021 in UK, Sweden, Italy, Netherlands and Belgium. N = 789 comparison of MM670G/MM770G pivotal with MiniMed™ 780G system  w/G4S CAS (Avg. 12.12 for MM670G and 7.61 for MiniMed™ 780G system  in a day)

Important Safety Information: MiniMed™ 780G system with SmartGuard™ Technology with Guardian™ 4 sensor

The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780GSystem includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, the Guardian™ 4 Transmitter, the Guardian™ 4 Sensor, One-press serter, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide Test Strips. The system requires a prescription from a healthcare professional.

The Guardian™ 4 Sensor is intended for use with the MiniMed™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian™ (4) sensor is indicated for up to seven days of continuous use.

The Guardian™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ 4 sensor. The Guardian™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.

WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult and the appropriate user guide at